摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲基-1-萘甲酸乙酯 | 103244-32-2

中文名称
2-甲基-1-萘甲酸乙酯
中文别名
——
英文名称
ethyl 2-methylnaphthalene-1-carboxylate
英文别名
ethyl 2-methyl-1-naphthalenecarboxylate;ethyl 2-methyl-1-naphthoate;2-Methyl-1-naphthoesaeure-ethylester;2-methyl-[1]naphthoic acid ethyl ester;2-methyl-1-naphthalenecarboxylic acid, ethyl ester;2-Methyl-[1]naphthoesaeure-aethylester
2-甲基-1-萘甲酸乙酯化学式
CAS
103244-32-2
化学式
C14H14O2
mdl
——
分子量
214.264
InChiKey
SVNMJCHGVZYPHV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Novel Potent 5-HT3 Receptor Ligands Based on the Pyrrolidone Structure: Synthesis, Biological Evaluation, and Computational Rationalization of the Ligand–Receptor Interaction Modalities
    作者:Andrea Cappelli、Maurizio Anzini、Salvatore Vomero、Laura Mennuni、Francesco Makovec、Edith Doucet、Michel Hamon、M.Cristina Menziani、Pier G. De Benedetti、Gianluca Giorgi、Carla Ghelardini、Simona Collina
    DOI:10.1016/s0968-0896(01)00332-7
    日期:2002.3
    Novel conformationally constrained derivatives of classical 5-HT(3) receptor antagonists were designed and synthesized with the aim of probing the central 5-HT(3) receptor recognition site in a systematic way. The newly-synthesized compounds were tested for their potential ability to inhibit [(3)H]granisetron specific binding to 5-HT(3) receptor in rat cortical membranes. These studies revealed subnanomolar
    设计并合成了新型5-HT(3)受体拮抗剂的新型构象受约束的衍生物,旨在以系统的方式探测中央5-HT(3)受体识别位点。测试了新合成的化合物在大鼠皮膜中抑制[(3)H]格兰司琼对5-HT(3)受体的特异性结合的潜在能力。这些研究揭示了一些正在研究的化合物的亚纳摩尔亲和力。发现该系列中最有效的配体是喹核苷衍生物(S)-7i,其显示出与参考配体格拉司琼相当的亲和力。在体外对NG 108-15细胞中的5-HT(3)受体依赖性[(14)C]胍鎓摄取进行了评估,对某些选定化合物的潜在5-HT(3)激动剂/拮抗剂活性进行了评估。在此功能测定中测试的两种托烷衍生物(7a和9a)均表现出拮抗特性,而研究的喹uc啶衍生物[化合物7i,8g和9g的对映体以及化合物(R)-8h]则显示了全部内在功效。因此,这些5-HT(3)受体配体的功能行为似乎受氮杂双环部分和杂芳族部分的结构特征影响。与在NG 108-15细胞
  • Novel 2′-alkoxymethyl substituted klavuzon derivatives as inhibitors of Topo I and CRM1
    作者:Hakkı Çetinkaya、Mehmet S. Yıldız、Meltem Kutluer、Aylin Alkan、Hasan Ozan Otaş、Ali Çağır
    DOI:10.1016/j.bioorg.2020.104162
    日期:2020.10
    3D spheroids. Among the tested klavuzon derivatives, isobutoxymethyl substituted klavuzon showed the highest selectivity of cytotoxic activity against pancreatic cancer cell line. They showed potent Topo I inhibition while their CRM1 inhibitory properties somehow diminished compared to 4′-alkylsubstituted klavuzons. The most cytotoxic 2′-methoxymethyl derivative inhibited the growth of the spheroids
    在这项工作中,由8个步骤从2-甲基-1-萘甲酸开始制备2'-烷氧基甲基取代的克拉维松衍生物。通过对癌细胞和健康的胰腺细胞株进行MTT细胞活力测试,以及通过超染色DNA松弛试验通过免疫染色和Topo I抑制特性,对HeLa细胞中的CRM1抑制特性进行评估,从而评估合成化合物的抗癌能力。它们的细胞毒性活性也存在于肝细胞癌细胞(HuH-7)衍生的3D球体中。在测试的克拉维松衍生物中,异丁氧基甲基取代的克拉维松对胰腺癌细胞系表现出最高的细胞毒活性选择性。与4'-烷基取代的克拉维松相比,它们显示出强力的Topo I抑制作用,而其CRM1抑制性能却有所降低。
  • PREPARATION AND USE OF MAGNESIUM AMIDES
    申请人:Clososki Giuliano Cesar
    公开号:US20100144516A1
    公开(公告)日:2010-06-10
    The present application relates to mixed Mg/Li amides of the general formula R 1 R 2 N—Mg—NR 3 R 4 .zLiY (II) wherein R 1 , R 2 , R 3 , and R 4 are, independently, selected from H, substituted or unsubstituted aryl or heteroaryl containing one or more heteroatoms, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or silyl derivatives thereof; and R 1 and R 2 together, or R 3 and R 4 together can be part of a cyclic or polymeric structure; and wherein at least one of R 1 and R 2 and at least one of R 3 and R 4 is other than H; Y is selected from the group consisting of F; Cl; Br; I; CN; SCN; NCO; HaIO n , wherein n=3 or 4 and Hal is selected from Ci, Br and I; NO 3 ; BF 4 ; PF 6 ; H; a carboxylate of the general formula R x CO 2 ; an alcoholate of the general formula OR x ; a thiolate of the general formula SR x ; R x P(O)O 2 ; or SCOR x ; or SCSR x ; O n SR x , wherein n=2 or 3; or NO n , wherein n=2 or 3; and a derivative thereof; wherein R X is a substituted or unsubstituted aryl or heteroaryl containing one or more heteroatoms, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or derivatives thereof, or H; m is O or 1; and z>1; as well as a process for the preparation of the mixed Mg/Li amides and the use of these amides, e.g. as bases.
    本申请涉及一般式为R1R2N—Mg—NR3R4.zLiY(II)的混合Mg/Li酰胺,其中R1、R2、R3和R4分别选择自H、含有一个或多个杂原子的取代或未取代的芳基或杂环芳基、线性、支链或环状、取代或未取代的烷基、烯基、炔基或其硅基衍生物;且R1和R2在一起,或R3和R4在一起可以是环状或聚合物结构的一部分;并且至少有一个R1和R2以及至少一个R3和R4不是H;Y选择自F、Cl、Br、I、CN、SCN、NCO、HaIOn,其中n=3或4,Hal选择自Ci、Br和I;NO3;BF4;PF6;H;一般式为RxCO2的羧酸盐;一般式为ORx的醇盐;一般式为SRx的硫醇盐;RxP(O)O2;或SCORx;或SCSRx;OnSRx,其中n=2或3;或NOn,其中n=2或3;及其衍生物;其中RX为取代或未取代的芳基或杂环芳基、线性、支链或环状、取代或未取代的烷基、烯基、炔基或其衍生物,或H;m为O或1;z>1;以及混合Mg/Li酰胺的制备方法和这些酰胺的用途,例如作为碱。
  • Preparation and Use of Magnesium Amides
    申请人:Knochel Paul
    公开号:US20090176988A1
    公开(公告)日:2009-07-09
    The present application relates to mixed Mg/Li amides of the general formula R1R2N—Mg(NR3R4)mX,m zLiY (II) wherein R 1 , R 2 , R 3 , and R 4 are, independently, selected from H, substituted or unsubstituted aryl or heteroaryl containing one or more heteroatoms, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or silyl derivatives thereof; and R 1 and R 2 together, or R 3 and R 4 together can be part of a cyclic or polymeric structure; and wherein at least one of R 1 and R 2 and at least one of R 3 and R is other than H; X and Y are, independently, selected from the group consisting of F; Cl; Br; I; CN; SCN; NCO; HalO n , wherein n=3 or 4 and Hal is selected from Cl, Br and I; NO 3 ; BF 4 ; PF 6 ; H; a carboxylate of the general formula R X CO 2 ; an alcoholate of the general formula ORX; a thiolate of the general formula SR X ; R X P(O)O 2 ; or SCOR X ; or SCSR X ; O n SR x , wherein n=2 or 3; or NO n , wherein n=2 or 3; and a derivative thereof; wherein R x is a substituted or unsubstituted aryl or heteroaryl containing one or more heteroatoms, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or derivatives thereof, or H; m is O or 1; and z>O; as well as a process for the preparation of the mixed Mg/Li amides and the use of these amides, e.g. as bases.
    本申请涉及到通式为R1R2N-Mg(NR3R4)mX,m zLiY(II)的混合镁/锂酰胺,其中R1,R2,R3和R4分别选择自H,含有一个或多个杂原子的取代或未取代芳基或杂芳基,线性,支链或环状,取代或未取代的烷基,烯基,炔基或其硅基衍生物; R1和R2在一起,或R3和R4在一起可以是一个环状或聚合物结构的一部分; 并且至少有一个R1和R2以及至少有一个R3和R不是H; X和Y分别选择自F; Cl; Br; I; CN; SCN; NCO; HalOn,其中n = 3或4,Hal选择自Cl,Br和I; NO3; BF4; PF6; H; 通式为RXCO2的羧酸盐; 通式为ORX的醇盐; 通式为SRX的硫醇盐; RXP(O)O2; 或SCORX; 或SCSRX; OnSRx,其中n = 2或3; 或NOn,其中n = 2或3; 及其衍生物; 其中R是取代或未取代的芳基或杂芳基,线性,支链或环状,取代或未取代的烷基,烯基,炔基或其衍生物,或H; m为O或1; z> O; 以及混合镁/锂酰胺的制备过程和这些酰胺的用途,例如作为碱。
  • US8134005B2
    申请人:——
    公开号:US8134005B2
    公开(公告)日:2012-03-13
查看更多